(Q37045165)

17 August 2017

1 reference

title

Early identification and treatment of insulin resistance: impact on subsequent prediabetes and type 2 diabetes (English)

1 reference

17 August 2017

0 references

1 reference

1 reference

Vivian A Fonseca

1

1 reference

17 August 2017

publication date

1 January 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

8 Suppl 7

1 reference

17 August 2017

page(s)

S7-18

1 reference

Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Correspondence between the adult treatment panel III criteria for metabolic syndrome and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Molecular mechanisms of insulin resistance and associated diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Hypertriglyceridemia, insulin resistance, and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Insulin resistance and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Point: impaired fasting glucose: The case for the new American Diabetes Association criterion.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Cardiometabolic risk assessment: an approach to the prevention of cardiovascular disease and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Does the metabolic syndrome exist?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Metabolic syndrome and hyperglycemia: congruence and divergence

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Atherosclerotic risk factors in Japanese subjects with isolated impaired fasting glucose and those with isolated impaired glucose tolerance according to 1997 and 2003 American Diabetes Association criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

All pre-diabetes is not the same: metabolic and vascular risks of impaired fasting glucose at 100 versus 110 mg/dl: the Screening for Impaired Glucose Tolerance study 1 (SIGT 1).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Using metabolic syndrome traits for efficient detection of impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

The Metabolic Syndrome and Glucose Tolerance Status Deterioration Over 23-Year Follow-Up

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Obesity and diabetes in the developing world--a growing challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

A 74-year-old woman with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Treatment of obesity: need to focus on high risk abdominally obese patients

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Weight gain as a risk factor for clinical diabetes mellitus in women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Effect of weight loss with lifestyle intervention on risk of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Protective mechanisms of the Mediterranean diet in obesity and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Scientific evidence of interventions using the Mediterranean diet: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Rationale and design of the Optimal Macro-Nutrient Intake Heart Trial to Prevent Heart Disease (OMNI-Heart).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

The changing roles of dietary carbohydrates: from simple to complex

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Dietary fat and diabetes: a consensus view

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Weight loss maintenance in severely obese adults after an intensive lifestyle intervention: 2- to 4-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

The DREAM trial – Authors' reply

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Prevention of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Acarbose in the treatment of elderly patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Recent findings concerning thiazolidinediones in the treatment of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Bone is a target for the antidiabetic compound rosiglitazone.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Thiazolidinediones in patients with diabetes mellitus and heart failure : implications of emerging data

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

Do thiazolidinediones cause heart failure? A critical review.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

1 reference

7 January 2021

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980017-2

7 January 2021

10.1016/S1098-3597(07)80017-2

Identifiers

DOI

1 reference

17 August 2017

1 reference